A simple HPLC assay for determining eltrombopag concentration in human serum. (29th December 2020)

• Record Type: Journal Article
• Authors: Yanagimachi, Naoya; Obara, Naoshi; Sakata‐Yanagimoto, Mamiko; Chiba, Shigeru; Doki, Kosuke; Homma, Masato
• Is Part Of: Biomedical chromatography. Volume 35:Number 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-29
• Subjects: eltrombopag -- HPLC analysis -- idiopathic thrombocytopenic purpura -- therapeutic drug monitoring; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.5049
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Eltrombopag, a thrombopoietin receptor agonist, is used for the treatment of idiopathic thrombocytopenic purpura (ITP) and aplastic anemia. We developed a HPLC assay for the determination of serum eltrombopag concentration in ITP patients. An aliquot of a serum sample spiked with diclofenac as the internal standard (IS) was treated with acetonitrile to precipitate the proteins. Eltrombopag and the IS were separated on an octadecylsilyl silica‐gel column using a mobile phase consisting of 10 mM 1‐pentanesulfonic acid sodium salt, acetonitrile, and acetic acid. The detection wavelength was set at 265 nm. The calibration curve was linear at the concentration range of 0.15–12.5 μg/mL for eltrombopag ( r = 0.9987). The recoveries of eltrombopag from the serum samples were greater than 95.9% with coefficients of variation (CVs) being less than 2.8%. The CVs for the intra‐day and inter‐day assays were 1.9–11.8% and 1.0–11.8%, respectively. This assay method could be used for therapeutic drug monitoring of eltrombopag in ITP patients.